Reduced expression of Tks5 leads to decreased growth of tumor cells <i>in vitro</i> and <i>in vivo</i>. by Barbara Blouw (715467)

Sis1-S49V, does not show decreased steady-state levels when expressed in Sc37 [PSI⁺] strain. by Melanie Y. Pullen (8933987)

Effects of Cu (5 µM) pretreatment on Hcy-induced decrease in cell viability and LDH release. by Daoyin Dong (424519)

Sign-tracking (ST)–Goal-tracking (GT) score for day 5. by Silvia Fuentes (4759686)

Purine nucleotides are decreased in long-term hypoxia. by Emily B. Cohen (9106088)

High Levels of SOX5 Decrease Proliferative Capacity of Human B Cells, but Permit Plasmablast Differentiation by Mirzokhid Rakhmanov (580449)

Adhesion strength is decreased in NEDD9−/− MEFs. by Jessie Zhong (171961)

2D and 3D AFM micrographs of fabricated samples (a) 5LZCM (b) 10LZCM (c) 15LZCM. by Md. Abu Daud (21485629)

Specificity of ChR2-YFP expression in DRN 5-HT neurons and efficiency of photostimulation <i>in vitro</i>. by Guillaume P. Dugué (620333)

Sphere-forming efficiency decreases following radiation. by Vicky T. Nguyen (5029244)

FTY720 decreases cerebral lymphocyte invasion. by Arthur Liesz (349478)

A Peptide Mimetic of 5-Acetylneuraminic Acid-Galactose Binds with High Avidity to Siglecs and NKG2D by Laura L. Eggink (760403)

“…In addition, the peptide bound the receptor NKG2D, which contains a lectin-like domain that binds Neu5Ac(α2,3)Gal. …”

Laquinimod prevents EAE and decreases encephalitogenicity of T cells. by Ulf Schulze-Topphoff (174453)

“…Representative FACS staining is shown including quantification (n = 4–5 mice per group). (E) Laquinimod decreases pathogenic potential of T cells. …”

Cediranib therapy decreases tumor blood volume. by Christian T. Farrar (355177)

“…<p>(left) After 2–3 days of treatment, a statistically significant (p<0.01) difference in the rCBV (±SEM) was observed between cediranib and control groups with a 16.5±2.2% decrease for cediranib treated animals and a 14.1±2.3% increase for control animals. …”

Vi expression decreases antibody and complement binding to <i>Salmonella</i> in the absence of specific antibodies. by Peter J. Hart (503558)

B2 decreases glycolytic intermediates in cells. by Craig Eyster (392633)

“…<b>(C)</b> Heatmap of targeted metabolomic data. Each column is a separate biological replicate (n = 5). The box indicates the clustering of decreased downstream glycolytic intermediates in B2-treated cells. …”

IR decreases but does not arrest ATC growth. by Vlad C. Sandulache (515406)

Backbone Isomerization to Enhance Thermal Stability and Decrease Mechanical Sensitivities of 10 Nitro-Substituted Bipyrazoles by Jingwei Meng (91923)

Backbone Isomerization to Enhance Thermal Stability and Decrease Mechanical Sensitivities of 10 Nitro-Substituted Bipyrazoles by Jingwei Meng (91923)

Backbone Isomerization to Enhance Thermal Stability and Decrease Mechanical Sensitivities of 10 Nitro-Substituted Bipyrazoles by Jingwei Meng (91923)